PhD | Business Development Senior Manager BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselaunch. ch
The Basel-based pharmaceutical company Novartis has launched a large-scale research study on multiple sclerosis (MS) that allows participants to contribute by sending data via their smartphones.
Novartis has three approved medications to treat MS along with other therapies in the development phase. The aim of the new study is to improve our understanding of the daily challenges patients with MS face and help make treatments more effective.
According to a statement, a mobile app was developed for the study to allow patients to contribute to the study from home or on the go by sending their medical data in real-time from their everyday environment.
“As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe,” said Stanley Cohan, medical director at the Providence Multiple Sclerosis Center in Portland, Oregon.
“With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”
Using smartphones, the app will capture participant responses to questionnaires as well as passive and active sensor-based movement data. Participants will also be able to use the app to view how their own data changes over time.